NCT05903430 A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
| NCT ID | NCT05903430 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Christie NHS Foundation Trust |
| Condition | Abdominal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-29 |
| Primary Completion | 2027-01-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-08-29 with a primary completion date of 2027-01-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
Eligibility Criteria
Inclusion criteria: 1. Have no MRI contra-indications. 2. Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines. 3. Be able to give informed consent. 4. Anticipated life-expectancy \> 6 months. 5. Not more than 3 oligmetastatic sites treated in total per patients. 6. Performance status ≤ 2. 7. Willing to attend follow-up and have details collected on prospective basis for a minimum of 1 year. Exclusion criteria: 1. Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. 2. Unable to tolerate MRI scans. 3. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study. 4. Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study. 5. Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05903430 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Abdominal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05903430 currently recruiting?
Yes, NCT05903430 is actively recruiting participants. Contact the research team at clare.griffin1@nhs.net for enrollment information.
Where is the NCT05903430 trial being conducted?
This trial is being conducted at Manchester, United Kingdom.
Who is sponsoring the NCT05903430 clinical trial?
NCT05903430 is sponsored by The Christie NHS Foundation Trust. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.